Why the study?
Does natriuretic peptide-guided therapy reduce heart failure readmissions and cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction?
Does natriuretic peptide-guided therapy reduce heart failure readmissions and cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction?
Answers are grounded in this paper and cite their sources.
This commentary discusses the expectations and context of the GUIDE-IT trial regarding natriuretic peptide-guided therapy in HFrEF.
The topic of guiding therapy in heart failure patients with natriuretic peptide levels is not new: eleven trials have been performed and several meta-analyses have been published including one with individual patient data (1). The GUIDE-IT trial should have been the trial that confirmed the meta-analyses that guiding therapy with natriuretic peptides in patients with heart failure would reduce the primary endpoint of heart failure readmissions and cardiovascular mortality by 20% (2,3).
No takes yet. Share an insight, caveat, or question.
Wouter E.M. Kok (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: